Background: Multiple myeloma that has progressed through proteasome inhibitors, immunomodulatory agents and anti-CD 38 antibodies has a poor prognosis. There is an urgent need for better therapies in this space. Teclistamab is a bi-specific monoclonal antibody that binds to CD3 on T-cells and B-cell maturation antigen (BCMA) on plasma cells thus leading…
Keep reading with a 7-day free trial
Subscribe to Hematology Oncology Snippets to keep reading this post and get 7 days of free access to the full post archives.